Dong-Hun Kang

Dong-Hun Kang

Auto-generated profile, based on publicly available information

Dong-Hun Kang

Department of Neurosurgery, School of Medicine, Kyungpook National University, Daegu, Korea

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
YKYong-Won Kim
Yong-Won Kim
JHJi Man Hong
Ji Man Hong
DPD.G. Park
D.G. Park
JCJin Wook Choi
Jin Wook Choi
DKD.-H. Kang
D.-H. Kang
JLJin Soo Lee
Jin Soo Lee
BACKGROUND AND PURPOSE: Although intracranial atherosclerotic disease is often encountered during endovascular treatment for acute vertebrobasilar occlusions, its clinical implication is not well-known. We aimed to evaluate whether intracranial atherosclerotic disease influences the clinical outcomes following endovascular treatment of acute vertebrobasilar occlusive stroke. MATERIALS AND METHODS: Fifty-one patients with acute vertebrobasilar occlusive stroke were included. The onset-to-groin puncture time was ≤12 hours, and aspiration- or stent-based thrombectomy was used as the primary treatment method. Following primary endovascular treatment, intracranial atherosclerotic disease (IAD group) was angiographically diagnosed when a fixed focal stenosis was observed at the occlusion site, whereas embolism (embolic group) was diagnosed if no stenosis was observed. Clinical and treatment variables were compared in both groups, and IAD was evaluated as a prognostic factor for clinical outcomes. RESULTS: The baseline NIHSS score tended to be lower (14 versus 22, P = .097) in the IAD group (n = 19) than in the embolic group (n = 32). The procedural time was longer in the IAD group (96 versus 61 minutes, P = .002), despite similar rates of TICI 2b–3 (89.5% versus 87.5%, P = 1.000). The NIHSS score at 7 days was higher (21 versus 8, P = .060) and poor outcomes (mRS 4–6 at 3 months) were more frequent in the IAD group (73.7% versus 43.8%, P = .038). IAD (odds ratio, 5.469; 95% CI, 1.09–27.58; P = .040) was independently associated with poor outcomes. CONCLUSIONS: An arterial occlusion related to IAD was associated with a longer procedural time and poorer clinical outcome. Further studies are warranted to elucidate the appropriate endovascular strategy.

1 January 2019 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
DKDong-Hun Kang
Dong-Hun Kang
Woong YoonWoong Yoon
Woong Yoon
Kang DH, et al. Korean J Radiol. 2019 May;20(5):739-748. https://doi.org/10.3348/kjr.2018.0809

22 July 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
SJS.H. Jang
S.H. Jang
SSSung-Il Sohn
Sung-Il Sohn
HPHyungjong Park
Hyungjong Park
SLSeong-Joon Lee
Seong-Joon Lee
YKYong-Won Kim
Yong-Won Kim
JHJeong-Ho Hong
Jeong-Ho Hong
The safety and efficacy of tirofiban during endovascular therapy in patients undergoing intravenous thrombolysis with recombinant IV tPA remain unclear. This study aimed to investigate the safety and efficacy of intra-arterial tirofiban use during endovascular therapy in patients treated with IV tPA. Using a multicenter registry, we enrolled patients with acute ischemic stroke who underwent endovascular therapy. Safety outcomes included postprocedural parenchymal hematoma type 2 and/or thick subarachnoid hemorrhage, intraventricular hemorrhage, and 3-month mortality. Efficacy outcomes included the successful reperfusion rate, postprocedural reocclusion, and good outcomes at 3 months (mRS scores of 0-2). The tirofiban effect on the outcomes was evaluated using a multivariable analysis while adjusting for potential confounders. Among enrolled patients, we identified 314 patients with stroke (279 and 35 patients in the no tirofiban and tirofiban groups, respectively) due to an intracranial artery occlusion who underwent endovascular therapy with intravenous thrombolysis. A multivariable analysis revealed no association of intra-arterial tirofiban with postprocedural parenchymal hematoma type and/or thick subarachnoid hemorrhage (adjusted OR, 1.07; 95% CI, 0.20-4.10; P = .918), intraventricular hemorrhage (adjusted OR, 0.43; 95% CI, 0.02-2.85; P = .467), and 3-month mortality (adjusted OR, 0.38; 95% CI, 0.04-1.87; P = .299). Intra-arterial tirofiban was not associated with good outcome (adjusted OR, 2.22; 95% CI, 0.89 -6.12; P = .099). Using intra-arterial tirofiban during endovascular therapy after IV tPA could be safe.

Verified
Journal Article
Open access
PDF file
JYJoonsang Yoo
Joonsang Yoo
JHJeong-Ho Hong
Jeong-Ho Hong
SLSeong-Joon Lee
Seong-Joon Lee
YKYong-Won Kim
Yong-Won Kim
JHJi Man Hong
Ji Man Hong
SSSung-Il Sohn
Sung-Il Sohn
Acute kidney injury (AKI) is often associated with the use of contrast agents. We evaluated the frequency of AKI, factors associated with AKI after endovascular treatment (EVT), and associations with AKI and clinical outcomes. We retrospectively analyzed consecutively enrolled patients with acute ischemic stroke who underwent EVT at three stroke centers in Korea. We compared the characteristics of patients with and without AKI and independent factors associated with AKI after EVT. We also investigated the effects of AKI on functional outcomes and mortality at 3 months. Of the 601 patients analyzed, 59 patients (9.8%) developed AKI and five patients (0.8%) started renal replacement therapy after EVT. In the multivariate analysis, diabetes mellitus (odds ratio (OR), 2.341; 95% CI, 1.283–4.269; p = 0.005), the contrast agent dose (OR, 1.107 per 10 mL; 95% CI, 1.032–1.187; p = 0.004), and unsuccessful reperfusion (OR, 1.909; 95% CI, 1.019–3.520; p = 0.040) were independently associated with AKI. The presence of AKI was associated with a poor functional outcome (OR, 5.145; 95% CI, 2.177–13.850; p < 0.001) and mortality (OR, 8.164; 95% CI, 4.046–16.709; p < 0.001) at 3 months. AKI may also affect the outcomes of ischemic stroke patients undergoing EVT. When implementing EVT, practitioners should be aware of these risk factors.

1 March 2020 in Radiology
Verified
Journal Article
Closed access
SLSeong-Joon Lee
Seong-Joon Lee
JHJi Man Hong
Ji Man Hong
JCJin Wook Choi
Jin Wook Choi
JPJi Hyun Park
Ji Hyun Park
BPBumhee Park
Bumhee Park
JLJin Soo Lee
Jin Soo Lee
In Korean patients undergoing endovascular treatment for vertebrobasilar occlusions, the composite of onset-to-puncture time of less than 8 hours, initial diffusion-weighted image volume of less th... Background The decision to perform endovascular treatment (EVT) for stroke related to vertebrobasilar occlusion (VBO) remains controversial. Purpose To identify preprocedural predictors of good out...

1 January 2016 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
YKYong-Won Kim
Yong-Won Kim
DKDong-Hun Kang
Dong-Hun Kang
YHYang-Ha Hwang
Yang-Ha Hwang
JPJaechan Park
Jaechan Park
YKYong-Sun Kim
Yong-Sun Kim
Kim YW, et al. J Korean Neurosurg Soc. 2016 Jul;59(4):379-384. http://dx.doi.org/10.3340/jkns.2016.59.4.379